Japanese company reaches $2bn deal to develop Alzheimer’s vaccine
Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease.
Japanese company reaches $2bn deal to develop Alzheimer’s vaccine
2T2C: Talent, Technology, Capital, Cognition

Japanese company reaches $2bn deal to develop Alzheimer’s vaccine

Photo: AFP/Nurphoto/Jakub Porzycki 
Eurasia 21/05/2024 12:25

Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease.

The vaccine is one of a wave of new drugs heading for the market, including lecanemab, developed by Japanese company Eisai, which received US regulatory approval last year, Financial Times reported.

In the Takeda deal, AC Immune will receive an upfront payment of $100mn, rising to $2.1bn if milestones are reached, as well as more than 10 per cent in royalties from any worldwide sales.

The Japanese group could advance the product to late-stage, phase 3 trials, AC Immune said, but regulatory approval could take several years.

Early trials had identified no safety concerns, said Andrea Pfeifer, chief executive of the biotech. But AC Immune would not have efficacy data for the drug until it completed a mid-stage trial within the next 12 months.
#Japan
See Also
The European hub for Chinese technological innovation
The European hub for Chinese technological innovation

This year marks the 75th anniversary of the establishment of diplomatic relations between China and Hungary. Hungary was the first country in Europe to join the Belt and Road Initiative (BRI) and to announce its policy of Eastern opening. The Comprehensive Strategic Partnership between the two countries in 2017 further deepened the framework for cooperation and opened new avenues for cooperation in areas such as infrastructure development, energy, finance and technology.
“Asia as Method” in higher education
“Asia as Method” in higher education

The evolving and more dynamic landscape of global education highlights the need for more inclusive and representative frameworks, leading to challenge the entrenched paradigms. One significant voice in this debate is Dr. Hongzhi Zhang, a distinguished Chinese scholar and one of the leading proponent of “Asia as Method” in higher education reform.

We use cookies on our website. If you consent to their use, we use them to measure and analyze the use of the website.
Information and Settings

Accept